WHAT'S NEW?

For further information on these and previous articles, visit the Archives.

PLEASE CHECK TO SEE IF YOUR DUES ARE CURRENT.  IF YOU NEED INFORMATION ON YOUR STATUS, CHECK WITH MAUREEN RUDEL, (989) 362-4747 OR maureen@tawasbay.net

IVERMECTIN'S SURPRISING POTENTIAL AGAINST CANCER
By James Stansbury, September 13, 2025

There is a safe and inexpensive cure for many types of cancer that is apparently being ignored by medical industrial complex and media. One possible reason why is because this new treatment protocol includes ivermectin (IVM). During the pandemic the use of this so-called “horse dewormer” was vigorously attacked by legacy media and banned as a COVID-19 treatment by the Biden administration’s FDA and CDC. India used it and had 10 times fewer deaths. Perhaps admitting that IVM worked would be embarrassing.

During the pandemic many courageous doctors were fired for questioning the government-mandated COVID-19 treatment protocol or warning of the dangerous mRNA vaccine side effects. Undaunted, several of these fired doctors joined forces to establish the Front Line Covid-19 Critical Care Alliance (FLCCC) to promote IVM and other repurposed drugs as safe, effective and economical solutions to treat COVID-19.

As the pandemic subsided, their mission expanded beyond COVID-19. I became aware of this change in May 2024 because of an Epoch Times video interview featuring Dr. Kathleen Ruddy, who had partnered with the FLCCC to research some intriguing evidence that IVM had remarkable potential as a cancer cure.

One case study she mentioned was a patient in late stage 4 prostate cancer near death. After she convinced him that he had nothing to lose by trying IVM, within a matter of months he was off his deathbed and back to work. (Joe Biden should take note). Dr. Ruddy also provided a very likely reason why the use of IVM as a cancer cure was being ignored. She said “…the pharmaceutical industries were not going to invest in a $0.10 pill.”

The FLCCC soon changed its name to the Independent Medical Alliance (IMA). Its new stated mission “is to save lives and promote long-term wellness through science-based, patient-centered care. Our protocols, widely adopted by healthcare providers worldwide, are grounded in the latest research and clinical data, empowering patients to take control of their health.”

Significantly, the IMA also has the science behind how IVM and other repurposed anti-parasite drugs like Fenbendazole and Mebendazole kill cancer cells. In addition, the IMA has also identified many other drugs and supplements such as vitamin D and green tea extract that also have cancer-fighting properties. Coincidentally these two supplements were also found helpful to treat COVID-19.

The key to understanding how these anti-parasite and other repurposed drugs kill cancer cells is explained in the IMA’s updated Guide to Stem Cells by Dr. Paul Marik and Dr. Justus Hope:

“The answer lies with a small population of cells that most standard treatments ignore. Cells that don’t just survive chemotherapy and radiation but adapt and return. They’re called cancer stem cells (CSCs), and they may be the single most overlooked driver of relapse, metastasis, and mortality in cancer care today.” (snip)

“Standard treatment protocols target the fast-dividing cancer cells. CSCs are more resistant and behave differently. They can stay dormant to evade detection, pump drugs out of their system, repair their DNA quickly, thrive in hostile, low-oxygen environments and hijack growth signals from the immune system and surrounding tissue. Adding to the problem, some chemotherapy and radiation protocols may actually stimulate CSCs -- making relapse more likely, not less.” (snip)

"CSCs are biologically wired to survive. They rely on powerful signaling pathways that govern cell survival, repair, and replication. …To beat CSCs, we have to interrupt these signals. The good news is: we can [interrupt them] with repurposed drugs and extremely safe compounds that are widely available."

A more practical document for cancer victims is available in the IMA’s free updated Cancer Care Guide that includes a comprehensive list of repurposed drugs and greater details about which combination of these drugs is best tailored for several different types of cancers (i.e., lung, breast, pancreatic, prostate, stage 4 metastatic diseases, etc.):

“The approach to each patient must be individualized based on the type and stage of the tumor, the tumor biology, the patients’ comorbidities and functional status and the patients’ preferences. Many patients may receive repurposed drugs and metabolic therapy as adjunctive therapy to conventional therapy from an oncologist while others may receive repurposed drugs and metabolic therapy alone. There is no ideal regimen; however, our approach is centered on the primary use of ivermectin, mebendazole, doxycycline and curcumin. It should be recognized that a subset of patients appear to either not respond to ivermectin or respond minimally to the initial ivermectin dose, but MAY respond to higher doses. It is essential that multiple cancer stem cell (CSC) pathways are blocked.”

The IMA cancer guide includes a disclaimer: “Cancer is a complicated disease, and patient care should be supervised by an integrative clinician; patients should not treat themselves.”

I know of no official approval of these treatment protocols by the FDA or CDC. Therefore, those anticipating surgery, radiation or chemo, may discover that their current oncologist is not allowed to prescribe any of these repurposed cancer fighting drugs. However, the IMA homepage has a link titled Resources to help find a provider or pharmacy in your region.

I’m no medical professional, but did endure radiation for my own prostate cancer six years ago. It was successful (PSA down to 0.004), but the common side effects are forever. I can’t help but wonder if the news about IVM had been known when my PSA number first jumped it may have eliminated the problem before radiation or surgery became necessary. It would have saved Medicare and Blue Cross a small fortune too.

I can only hope the IMA’s new cancer treatment protocols have a high priority in RFK Jr.'s MAHA playbook because Dr. Marik plainly stated that “…despite decades of research and over $200 billion spent annually, cancer rates continue to rise.”

Reprinted with permission from the American Thinker: https://www.americanthinker.com

TRUMP'S IMMIGRATION RESET: H-1AND GOLD CARD ORDERS PUT AMERICA FIRST
By Brian C. Joondeph, September 23, 2025

President Donald Trump’s two recent executive orders, one imposing a $100,000 annual fee on H-1B visas and the other launching the “Gold Card” fast-track residency program, represent the most significant immigration reforms in decades.

They flip the incentive structure that has for years favored multinational corporations and global outsourcing firms over American workers, while also tackling long-ignored national security risks.

As a policy, open borders is one area where Democrats and many Republicans agree. Democrats want new voters, while the Chamber of Commerce and Wall Street Journal Republicans want cheap labor. President George W. Bush, backed by Senator John McCain, in 2007, pushed for “comprehensive immigration reform,” a euphemism for amnesty, for millions of illegal aliens, which fortunately failed a US Senate vote.

Enter President Trump, the only president in my lifetime who has recognized that America has a sovereign border. Even President Reagan failed to repair our dysfunctional immigration system. He signed an amnesty bill into law, which NPR heralded as “a Reagan legacy,” and it unsurprisingly turned California from a red to a blue state. No wonder NPR loved it.

The H-1B program was initially created to help U.S. companies fill rare, high-skilled roles when American expertise was unavailable.

However, in practice, it has become a pathway for cheap foreign labor. According to the Economic Policy Institute (EPI), in 2022, the top 30 H-1B employers brought in 34,000 new visa workers even as they laid off at least 85,000 Americans. From MAGA to making the rest of the world great again.

The proportion of IT workers on H-1Bs has risen from 32% in 2003 to over 65% today, even as unemployment among recent computer science graduates remains above six percent, according to the White House.

Trump’s order significantly alters the landscape.

Companies now face a $100,000 annual fee per H-1B visa, rather than just a one-time filing fee, according to the White House. This ongoing expense is meant to give employers pause. Is the skill truly so scarce that it justifies paying $100,000 annually to Washington, D.C., in addition to salary and benefits? If so, that’s acceptable, but the era of flooding payrolls with lower-cost foreign contractors has ended.

Commerce Secretary Howard Lutnick clarified, “The whole idea is no more with these big tech companies or other large corporations training foreign workers. They have to pay the government $100,000, and then they have to pay the employee.”

To emphasize, this is an annual fee, not a one-time payment. The fee expires after one year unless renewed.

Perhaps the most damaging effect of the H-1B system has been on young Americans considering careers in science, technology, engineering, and mathematics. Why spend years earning a STEM degree, at great personal expense, when companies like Amazon and Microsoft prefer cheaper contractors from abroad? The White House itself warned that the H-1B program is creating “disincentives for future American workers to choose STEM careers.”

That chilling effect has serious consequences. When American graduates see their job opportunities cut by a surge of imported labor, many choose to leave critical fields altogether. In the long run, this not only harms wages but also weakens the nation’s innovation pipeline. Trump’s order restores fair competition and keeps STEM careers open for U.S. students.

It’s not literal slavery, but it amounts to modern-day indentured servitude with workers tied to one employer, unable to leave without risking deportation.

The debate extends beyond just economics. Allowing tens of thousands of foreign nationals, many from strategic competitors like China, to work in sensitive sectors such as semiconductors, defense, and telecommunications poses serious national security risks. Intellectual property theft, espionage, and divided loyalties are real threats, not just theories. They have been repeatedly documented by U.S. intelligence agencies.

By tightening the H-1B pipeline, Trump’s executive action reduces this exposure. America cannot afford to have its cutting-edge military and technology sectors mainly staffed by non-citizens. Conservatives have long argued that border security and economic security are connected. Trump’s order makes clear that high-skill visas are no exception.

Ross Perot, when running for president in 1992, famously warned, “You’re going to hear a giant sucking sound of jobs going south” due to American jobs leaving the country over NAFTA.

Back then, the threat was factories moving overseas.

Today, the sound is different, but the effect is the same. American workers are being replaced, this time by imported labor under H-1B. Trump’s reforms respond to Perot’s warning a generation later by using executive authority to keep jobs with American citizens.

If the H-1B order closes the cheap-labor loophole, the Gold Card program opens a new, carefully targeted door.

For a $1 million gift to the U.S. government, wealthy individuals can obtain a green card through expedited review. Corporations can sponsor key employees for $2 million, while a proposed Platinum Card at $5 million could someday provide a path to citizenship. Applicants still must pass background checks and meet immigration law requirements. The only difference is their position in line, which they leap to the front.

This approach addresses two issues simultaneously. First, it monetizes efficiency by having applicants pay for expedited processing instead of taxpayers funding an overcrowded immigration system. Second, it makes sure that those who skip ahead are likely to be job creators and investors, not liabilities. As CBS News reported, Trump explained: “We’re going to have great people coming in, and they’re going to be paying.”

Such programs are common. Portugal offers a Golden Visa program that requires a five-year investment in monetary assets for residency, which is less direct and efficient compared to Trump’s proposal.

For conservatives cautious about unrestricted immigration, this presents a strong bargain: America gains capital instead of bearing costs.

Unsurprisingly, Big Tech is unhappy. Venture capitalists argue that the $100,000 H-1B fee could hurt America’s competitiveness, but this overlooks how the current system has suppressed domestic innovation by discouraging Americans from pursuing STEM careers. Genuine innovation thrives when American students and workers believe they can compete fairly.

Foreign governments have also expressed concern, especially India, which depends heavily on exporting workers to the U.S.

However, “mutual benefits” cannot mean ongoing disadvantages for American workers. If Indian talent is truly essential, companies can pay higher fees or opt for the Gold Card route.

These executive orders achieve what years of congressional debate failed to do -- they restore fairness and balance. They send a clear message that American jobs and national security come first, while still welcoming genuine talent and investment. This is true MAGA.

Critics might question the legality of Trump’s actions, and courts could intervene. Some far-left judges are probably already preparing their restraining orders and injunctions. But Trump is not changing immigration law itself, only the process, which is controlled by the executive branch.

The political message is clear. Under this administration, immigration policy is no longer aimed at boosting corporate profits or appeasing foreign governments. Instead, it is focused on defending the American worker, supporting the American student, and securing America’s future.

Contrast this with the Biden administration, which has allowed record levels of illegal border crossings. Trump has sealed the border and is now fixing a broken immigration system.

President Trump’s dual actions on immigration, the H-1B overhaul and the Gold Card launch, are bold, controversial, and exactly what conservatives have demanded for years.

By making H-1Bs prohibitively expensive each year, he fights wage suppression, encourages Americans to pursue STEM fields, and addresses national security concerns. Simultaneously, the Gold Card provides a practical, revenue-generating pathway for the world’s most talented entrepreneurs and investors to come to America legally.

This is what immigration policy should be -- tough, fair, and unapologetically MAGA pro-American.

Brian C. Joondeph, M.D., is a physician and writer. Follow me on Twitter @retinaldoctor, Substack Dr. Brian’s Substack, Truth Social @BrianJoondeph, LinkedIn @Brian Joondeph, and by email brianjoondeph@gmail.com.

Reprinted with permission from the American Thinker: https://www.americanthinker.com